Alnylam's Biotherapeutics Unit Could Strike Industry Deals in 'Near Term'

Expected to help drive this quick adoption is the technology's potential use in improving the manufacture of existing drugs, not just "products that are in the development stages within the biotherapeutics marketplace," according to Alnylam's CEO.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.